Rani Therapeutics Holdings Earnings Call Transcripts
Fiscal Year 2026
-
The company showcased its RaniPill technology for oral biologic delivery, highlighted a major partnership with Chugai, and reported strong clinical data for RT-114. Manufacturing scale-up and a robust cash position support ongoing clinical and partnership milestones, with additional collaborations and portfolio expansion in obesity and metabolic diseases planned.
-
A novel oral biologics platform demonstrated strong phase I-A results for RT-114, with over 150% bioavailability and no new safety concerns. Strategic partnerships, including a $1B Chugai deal and collaborations with ProGen and PegBio, support a robust pipeline in obesity and immunology.
-
The meeting confirmed quorum, elected seven directors, and ratified the auditor. Major highlights included a $1.085 billion Chugai partnership, significant financing rounds, and progress in clinical programs RT-114 and RT-116, positioning the company for future growth.
Fiscal Year 2025
-
Significant progress was made in 2025, including a major Chugai partnership, strong pipeline advances, and improved financials with a cash runway into Q4 2027. RT-114 entered phase I trials, and the company is now debt-free.
Fiscal Year 2024
-
Rani advanced its RaniPill platform with strong preclinical results for RT-114 and RT-116, targeting the obesity market with differentiated oral biologics. Financial discipline reduced expenses and extended cash runway into Q3 2025, with RT-114 clinical trials planned for mid-2025.
-
The RaniPill platform enables oral delivery of biologics using a dissolvable microneedle, with strong safety data and low manufacturing costs. Key programs include phase 2-ready RT-111 and an obesity drug entering phase 1 next year. Partnerships and robust IP position support future growth.
-
RaniPill technology enables oral delivery of biologics with bioavailability matching injections, supported by strong patent protection and flexible dosing. Lead programs target obesity and autoimmune diseases, with strategic partnerships and a cash runway into Q3 2025.
-
RaniPill technology enables oral delivery of biologics, showing strong patient preference and comparable bioavailability to injectables. Key programs include RT-114 for obesity and RT-111 as a biosimilar Stelara, both with differentiated dosing and efficacy. Recent financing extends runway into Q3 2025.
-
RaniPill technology enables oral delivery of biologics, targeting high-value markets like obesity and immunology. The lead obesity program, in partnership with ProGen, is advancing toward clinical trials with promising early data and aims for differentiated dosing and tolerability.
-
A novel oral delivery platform is advancing a dual GLP-1/GLP-2 agonist for obesity, aiming for weekly or monthly dosing and leveraging a strong partnership and robust safety data. Phase 1 trials are set for early 2025, with further pipeline expansion and manufacturing scale-up underway.
-
A 50/50 partnership will develop RT-114, an oral GLP-1/GLP-2 dual agonist for obesity, leveraging RaniPill technology for high bioavailability and weekly dosing. RT-114 aims to match injectable efficacy with lower API use and improved tolerability, with phase I trials planned for early 2025.